%0 Generic
%A Cho, B. C.
%A Rodriguez-Abreu, D.
%A Hussein, M.
%A Cobo, M.
%A Patel, A.
%A Secen, N.
%A Gerstner, G.
%A Kim, D-W.
%A Lee, Y-G.
%A Su, W-C.
%A Huang, E.
%A Patil, N.
%A Huang, M.
%A Zhang, Z.
%A Wen, X.
%A Mendus, D.
%A Hoang, T.
%A Meng, R.
%A Johnson, M. L.
%T Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/24517
%~